Michael A. Carducci, M.D., FACP

AEGON Professor in Prostate Cancer Research
Professor of Oncology

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Johns Hopkins University School of Medicine

Professor of Urology
Brady Urological Institute
The Johns Hopkins University School of Medicine

Address:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Skip Viragh Building, Floor 9- 9150 201 N. Broadway Baltimore, MD 21287

Appointments: (410) 614-3977

Email: carducci@jhmi.edu

Fax: (410) 614-8160

Michael A. Carducci, MD, is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine.  He is the Associate Cancer Center Director for Clinical Research within the Johns Hopkins Kimmel Cancer Center. He is the Regional Research Director for the National Capital Region for the Kimmel Cancer Center.   Overall, his clinical and research focus is on the development and evaluation of new therapies for urologic cancers.  Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci.  To complete these studies, Dr. Carducci facilitates and brings together a multi-disciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care.  He is a member of the Miller-Coulson Academy of Clinical Excellence at Johns Hopkins. 

A Fellow of the American College of Physicians and a Fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his laboratory and clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation.  Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards.  Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He is the Chair of the Genitourinary Oncology Committee of ECOG-ACRIN, and an active member of the GU Steering Committee for the NCI.  Dr. Carducci is Co-Chair of the Investigational Drug Steering Committee for the NCI.  He is an Associate Editor for GU Cancers for the Journal of Clinical Oncology.   

A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital.

Professional Experience

1995 - 96 

Instructor of Oncology and Urology
The Johns Hopkins University
Baltimore, Maryland

1996 - 2001

Assistant Professor of Oncology and Urology
The Johns Hopkins University Baltimore, Maryland

2001 - 2007
Associate Professor of Oncology and Urology
The Johns Hopkins University Baltimore, Maryland
2008 -
Professor of Oncology and Urology
The Johns Hopkins University Baltimore, Maryland

Educational and Academic Experiences

1975 - 79 

Bishop Moore High School
Orlando, Florida

1979 - 83

A.B. - American Studies
Georgetown University
Washington, D.C.

1983 - 84
Wayne State University
Detroit, Michigan
Non-degree Post-baccalaureate coursework
1984 - 88
M.D., Wayne State University School of Medicine
Detroit, Michigan
1988 - 89
Intern in Internal Medicine
University of Colorado Health Sciences Center
Denver, Colorado
1989 - 91
Resident in Internal Medicine
University of Colorado Health Sciences Center
Denver, Colorado
1991 - 92
Chief Resident in Internal Medicine
University of Colorado Health Sciences Center
Denver, Colorado
1991 - 92
Staff Physician Department of Veterans Affairs
Denver, Colorado
1991 - 92
Medical Staff Physician
Denver Health and Hospitals Denver General Hospital
Denver, Colorado
1992 - 95
Senior Clinical Fellow, Medical Oncology
The Johns Hopkins Oncology Center
The Johns Hopkins Hospital
Baltimore, Maryland
1993 - 95
Post-Doctoral Research Fellow
Laboratory of Jonathan W. Simons, M.D.
The Johns Hopkins Oncology Center
Baltimore, Maryland

Publications

 Free Access to abstracts at PubMed

Peer-Reviewed Original Research Articles (H-index – 75 (Scopus))

  1. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, and Simons JW.  Interleukin 6:  A candidate gene product in the molecular biology of human prostate cancer morbidity.  Urology. 1995: 45: 542-549.
  2. Carducci MA, Ayyagari SA, Sanda MG, Simons JW.  Gene therapy for prostate cancer: translational research from the Dunning prostate cancer model.  Cancer.1995; 75: 2013-2020.
  3. Carducci MA, Nelson JB, Chan-Tack K, Ayyagari SR, Sweatt WH, Campbell PS, Nelson WG,  Simons JW.  Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate.  Clin Can Res.1996; 2:379-385.
  4. Carducci MA, Abrams R, Yeo C, Hruban RV, Zahurak M, Cameron J, Grochow L.  Early evaluation of abdominal/hepatic irradiation and 5-FU/Leucovorin after pancreaticoduodenectomy.  Intl Jour of Radiation Onc, Biology, Physics.  1996; 35:143-150.
  5. Simons JW, Jaffee EM, Weber C, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen L, Finn CC, Clift SM, Hauda KM, Owens AH, Pardoll DM, Piantadosi S,  Dranoff G, Mulligan RC,  Marshall FF.  Bioactivity of human GM-CSF gene transfer in autologous irradiated renal cell carcinoma vaccines.  Cancer Research. 1997; 57:1537- 1546.
  6. Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, Bolton WE.  Impaired    expression and function of signal transducing z-Chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry. 1998; 32: 109-119.
  7. Carducci MA, Choti MA, Maestri NE, Brusilow SW.  Allopurinol-induced pyrimidinuria in cancer patients.  In Vivo. 1998; 12: 271-274.
  8. Pelidis MA, Carducci MA, Simons JW.  Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. International Journal of Oncology. 1998; 12: 889-893.
  9. Carducci MA, Piantadosi S, Pound CR, Epstein JI, Simons JW, Marshall FF, Partin A.  Nuclear morphometry adds significant prognostic information to stage and grade of renal cell carcinoma.  Urology. 1999; 53: 44-49.
  10. Simons JW, Mikhak B, Chang J-F, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter B, Piantadosi S, Marshall FF, Nelson WG.  Induction of immunity to prostate cancer antigens:  Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete GM-CSF using ex-vivo gene transfer. Cancer Res.  1999; 59: 5160-5168.
  11. Bubley GJ, Carducci MA, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP,Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G.  Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: recommendations from the PSA working group. J Clin Oncol.  1999; 17: 1-7.
  12. Sinibaldi VJW, Carducci M, Laufer M, Eisenberger M.  Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.  Semin Oncol.  1999; 26 (Suppl 17) 45-48.
  13. Laufer M, Sinibaldi VJ, Carducci MA, Eisenberger MA.  Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer. Urology. 1999; 54: 745.
  14. Wang, Z-.P, Eisenberger MA, Carducci MA, Partin AW, Scher HI,  T’so POP.  Identification and characterization of circulating prostate cancer cells.  Cancer. 2000; 88: 2787-2795.
  15. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicols S, Oh W, and Stadler W.  A phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.  J Clin Oncol.  2000; 18:1921-1927.
  16. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.  Cancer cells engineered to secrete granulocyte-macrophage colony stimulating factor using ex-vivo gene transfer as vaccines for the treatment of genitourinary malignancies.  Cancer Chemother Pharmacol. 2000; 46: S67-72.
  17. Pili R, Kruszewski MP, Hager B, Lantz J, Carducci MA.  Combination of phenylbutyrate and 13-cis-retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 2001; 61: 1477 – 1485.
  18. Carducci MA, Gilbert J, Bowling MK, Eisenberger MA, Sinibaldi V, Noe D, Chen TL, Grochow LB, Donehower RC.  A phase I clinical and pharmacologic evaluation of sodium phenylbutyrate on a 120 hours infusion schedule.  Clin Cancer Res. 2001; 7: 3047-3055.
  19. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA.   A phase I dose escalation trial to maximally tolerated dose of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001; 7: 2292 - 2300.
  20. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci MA, Han M, Epstein JI, Eisenberger MA, Walsh PC, Partin AW.  Contemporary identification of patients at high risk for early prostate cancer recurrence following radical retropubic prostatectomy. Urology. 2001; 57: 1033-1037.
  21. DeWeese TL, Mikhak B, Drew R, Goemann M, Li S, Hamper U, DeJong R, Detorie N, van der Poel H, Rodriquez R, Haulk T, DeMarzo AM, Piantadosi, S, Carducci MA, Nelson WG, Simons JW.  A phase I trial of intraprostatic CN706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of prostate cancer which is locally-recurrent following radiation therapy.  Cancer Res. 2001; 61: 7464-7472.
  22. Van der Poel HG, McCadden J, Verhaegh GW, Kruszewski M, Ferrer F, Schalken JA, Carducci M, Rodriguez R.  A novel method for the determination of basal gene expression of tissue specific promoters:  An analysis of prostate specific promoters.   Cancer Gene Ther. 2001; 8: 927-935.
  23. Heath EI, O’Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB.  Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumors.  Cancer Chemother Pharmacol. 2001; 48:269-274.
  24. Carducci MA, Bowling MK, Rogers T,  Eisenberger M, Sinibaldi V, Donehower R, Leahy T,  Moyse D, Carr R, Isaacson J, Janus TJ, Padley RJ, Nelson JB.  Atrasentan, an endothelin receptor antagonist for refractory adenocarcinomas: Phase I and pharmacologic evaluation.  J Clin Oncol. 2002; 20: 2171-2180.
  25. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA.   Phase II evaluation of docetaxel plus one day oral estramustine phosphate in the treatment of androgen independent prostate cancer.  Cancer. 2002; 94: 1457-1465.
  26. Li Y, McCadden J. Ferrer F, Kruszewski M, Carducci M, Simons J, Rodriguez R.  Prostate-specific expression of the diptheria tox A chain: Studies of inducibility and specificity of expression of prostate-specifc antigen promoter-driven DT-A adenoviral mediated gene transfer.  Cancer Res. 2002; 62: 2576-2582.
  27. Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.  Long – term effects of androgen deprivation therapy in prostate cancer patients.  Clin Endocrinol. 2002; 56: 779-786.
  28. Heath EI, DeWeese TL, Partin AW, DeMarzo AM, Groopman JD, Nelson WG, Rodriguez R, Piantadosi SA, Carter HB, Schoenberg MP, Yang VW, Hubbard WC, Dannenberg AJ, Lieberman R, Walczak J, Gurganus R, Stewart J, Carducci MA.  The design of a randomized, placebo-controlled trial of celecoxib in pre-prostatatectomy men with clinically localized adenocarcinoma of the prostate.  Clin Prostate Cancer. 2002; 1: 182-187.
  29. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA,  Schmitt JL, Nelson JB.  The effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: A randomized, placebo controlled trial. J Clin Oncol. 2003; 21: 679-689.
  30. Nelson JB, Nabulsi AA, Vogelzang NNJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA.  Suppression of prostate cancer-induced bone remodeling by the endothelin receptor A antagonist, atrasentan.  J Urology. 2003; 169: 1143-1149.
  31. Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD.  Phase I study of DHA-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.  Clin Cancer Res. 2003; 9: 3589-3597.
  32. Eisenberger MA, Laufer M, Vogelzang N, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D.  Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY-320236) in prostate cancer: Insights on the possible mechanism of action.  Urology. 2004; 63: 114-119.
  33. Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AW, Logothetis C, Soule H.  Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group.  J Clin Oncol. 2004; 22: 537-556.
  34. Sunkara U, Walczak J, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff C, Sinibaldi V, Carducci M. A phase II trial of temozolamide and interferon-alpha in patients with advanced renal cell carcinoma.  J of Interferon and Cytokine Res. 2004; 24: 37-41.
  35. Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A.  Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by LC/MS/MS.  Anal Biochem. 2004; 324: 276-284.
  36. Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA.  Comparative pharmacokinetics of weekly and every 3-week docetaxel.  Clin Cancer Res. 2004; 10: 1976-1983.
  37. Kaufman DS, Carducci MA, Kuzel T, Todd MB, Oh WK, Smith MR, Nicol SJ, Stadler WM.  A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.  Urol Oncol. 2004; 22: 393-397.
  38. Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN Jr. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic Modifier.  Bioconjug Chem. 2004; 15: 1416-1423.
  39. Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD.  Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry with high-performance liquid chromatography.  J Chromatog B. 2004; 813: 81-88.
  40. Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD. Corrigendum to “ Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry with high-performance liquid chromatography.”  J Chromatog B Analyt Biomed Life Sci.  2016; 1020:167. Epub 2016 Mar 25.
  41. Baker SD, van Schaik RHN, Rivory LP, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, ten Tije AJ, Verweij J, Sparreboom A.  Factors affecting cytochromome P-450 3A activity in cancer patients.  Clin Cancer Res. 2004; 10: 8341-8350.
  42. Lin K-S, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen M-K, Brenneman K, Pili R, Pomper M, Carducci MA, Wagner HN.  A new high affinty technetium-99m-bombesin analogue with low abdominal accumulation.  Bioconjugate Chem. 2005; 16: 43-50.
  43. Dees EC, Baker SD, O’Reilly S, Rudek MA, Davidson SB, Aylesworth C, Elza-Brown K, Carducci MA, Donehower RC.  A phase I and pharmacokinetic study of short infusions of the protein kinase C inhibitor UCN-01 in patients with refractory solid tumors.  Clin Cancer Res. 2005; 11: 664-671.
  44. ten Tije AJ, Verweij J, Carducci MA, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD.  Prospective evaluation of the pharmacokinetics, CYP3A phenotype, and toxicity profile of docetaxel in the elderly.  J Clin Oncol. 2005; 23: 1070-1077.
  45. Phupanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA.  Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A Phase I clinical and pharmacological study.  Neuro Oncol. 2005; 7: 177-182.
  46. Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD.  Pharmacokinetics of 5-azacytidine given with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol. 2005; 23: 3906-3911. 
  47. Carducci MA, Carrol PR.  Multidisciplinary managemenet of advanced prostate cancer: Changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.  Urol. 2005; 65(S5A) 18-22.
  48. Rosenbaum E, Zahurak  M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA.  Marimistat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized double blind Phase I/II trial.  Clin Cancer Res., 2005; 11: 4437-4443.
  49. Huie M, Carducci M, Liu G, Wilding G, Marnocha R, Izquierda M, Thomas J.  Phase I trial of piritrexim and gemcitabine in patients with advanced solid tumors.  Am J Clin Oncol.  2005; 28: 613-617.
  50. Basaria S, Muller D, Carducci M, Egan J, Dobs AS.  Hyperglycemia and insulin resistance in men with prostate cancer undergoing androgen deprivation therapy.  Cancer.  2006; 106: 581-588.
  51. Messersmith WA, Baker SD, Lassiter L, Sullivan RA, Dinh K, Almuete VI, Wright JJ, Donehower RC, Carducci MA, Armstrong DK. Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors.  Clin Cancer Res. 2006; 12: 1270-1275.
  52. Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, Morton R, See W, Sweeney C, Liu G, Dreicer R, DiPaola R.  The future of phase II clinical trial design: Methods in translational research from the genitourinary committee of the Eastern Cooperative Oncology Group.  Clin Cancer Res.  2006; 12: 1966-1969.
  53. Braga-Basaria M, Muller DC, Carducci MA, Egan J, Dobs AS, Basaria S.  Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Intl J Impot Res. 2006; 18: 494-498.
  54. Gilbert J, Carducci MA, Dees EC, Baker SD, Donehower RD.  A Phase I study of the oral anti-metabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.  Invest New Drugs.  2006; 24: 499-508.
  55. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummerson L,Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G.  A Phase I trial of intravenous CG7870, a replication-selective PSA-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.  MolTher. 2006; 14: 107-117.
  56. Green LJ, Marder P, Ray C, Cook CA, Jaken S, Herbst R, Carducci M, Britten C, Basche M, Eckhardt G, Thornton D.  Development and validation of a drug activity biomarker that demonstrates target inhibition in cancer patients receiving enzastaurin, a novel phospho-kinase C-β inhibitor. Clin Cancer Res. 2006; 12: 3408-3415.
  57. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift Sm, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG.  Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.  Clin Cancer Res. 2006; 12: 3394-3401.
  58. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD,  Manning J, Jiemjit A, Dover G, Mays A, Zweibel J, Murgo A, Weng L-J, Herman J.  Combined DNA methyltransferase and histone deacetylation inhibition in the treatment of myeloid neoplasms.  Cancer Res. 2006; 66: 6361-6369.
  59. Maggio M, Blackford A, Taub D, Carducci M, Ble A, Metter J, Braga-Basaria M, Dobs A, Basaria S.  Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl.  2006; 27; 725-728.
  60. Xia Q, Sung J, Chowdhury W, Chen C-L, Hoti N, Shabbeer S, Carducci M, Rodriquez R.  Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro.  Cancer Res. 2006; 66: 7237-7244.
  61. Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R,  Walczak J, Baker SD, Zahurak M, Carducci MA.  Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.  Am J Clinical Oncol. 2006; 29: 395-398.
  62. Braga-Basaria M, Muller DC, Carducci MA, Egan J, John M, Dobs AS, Basaria S.  Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy.  J Clin Oncol.  2006; 24: 3979-3983.
  63. Carducci MA, Musib L, Kies M, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Stewart J, Enas N, Sinha V, Thornton DE, Herbst RS. Dose escalation and pharmacokinetics of enzastaurin (LY317615), an oral PKCβ inhibitor, in patients with advanced cancer: a Phase I study.  J Clin Oncol. 2006; 24: 4092-4099.
  64. Qian DZ, Kachhap SK, Collis SJ, Verheul HMW, Carducci MA, Atadja P, Pili R. Class II histone deacetylases are associated with VHL independent regulation on HIF-1α.  Cancer Res. 2006; 66: 8814-8821.
  65. Levy MH, Back A, Bazargan S, Benedetti C, Billings JA, Block S, Bruera E, Carducci MA, Dy S, Eberle C, Foley KM, Harris JD, Knight SJ, Milch R, Rhiner M, Slatkin NE, Spiegel D, Sutton L, Urba S, Von Roenn JH, Weinstein SM.  Palliative Care.  J Natl Compr Canc Netw. 2006; 4: 776-818.
  66. Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins C, Colevas AD, Donehower RC, Carducci MA, Wolff AC.  Phase I study of continuous weekly dosing of dimethyl benzolphenylureas (BPU) in patients with solid tumors.  Europ J Cancer. 2007; 43: 78-86. Epub 2006 Nov 3.
  67. Motzer RJ,  Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J. Kidney cancer.  J Natl Compr Canc Netw. 2006; 4: 1072-1081.
  68. Motzer RJ,  Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J. Testicular Cancer.  J Natl Compr Canc Netw. 2006; 4: 1038-1058.
  69. Verheul HMW, Qian DZ, Carducci MA, Pili R.   Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.  Cancer Chemother Pharmacol, 2007; 60:329-339. [Epub 2007 Jan 26].
  70. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, Ruether D, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse D, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW.  ASCENT: A double-blinded randomized study of DN-101 (high dose calcitriol) plus docetaxel versus placebo  plus docetaxel in androgen –independent prostate cancer.  J Clin Oncol, 2007; 25: 669-674.
  71. Snyder CF, Dy SM, Hendricks DE, Brahmer JR, Carducci MA, Wolff AC, Wu AW.  Asking the right questions: Investigating needs assessments and health-related quality of life questionaires for use in oncology clinical practice. Suppor Care Cancer, 2007, 15:1075-1085.  [Epub 2007 Feb 21].
  72. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, Deweese TL. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.  Urology 2007; 69:626-531.
  73. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer.  Arch Int Med, 2007; 167:612-613.
  74. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith W, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC.  Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chem Pharmacol, 2008; 61: 423-433. [Epub 2007 Apr 12].
  75. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawskka E, Sosman J, Atkins M, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, Galand L, Thiele A, O’Toole T, Kong S, Park Y, Moore L, Motzer R.  Temsirolimus, interferon, or the combination of interferon plus temsirolimus for patients with advanced renal cell carcinoma and poor risk features. N Engl J Med, 2007; 356:2271-2281.
  76. Zhou S, Kachhap S, Sun W, Wu G, Chuang A, Poeta L, Grumbine L, Mithani S, Chatterjee A, Koch W, Westra W, Maitra A, Glazer C, Carducci M, Sidransky S, Mcfate T, Verma A, Califano JA.  Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci. 2007; 104: 7540-7545. [Epub 2007 Apr 24].
  77. Shabbeer S, Kortenhorst M, Kachhap S, Galloway N, Rodriguez R, Carducci MA.  Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.  The Prostate, 2007; 67: 1099-1110.
  78. Armstrong A, Garrett-Mayer E, Ou Yang YC, Carducci M, Tannock I, de Wit R, Eisenberger M.  PSA and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.  J Clin Oncol, 2007; 25:3965-3970.
  79. Kachhap S, Faith D, Qian D, Shabbeer S, Galloway N, Pili R, Denmeade S, DeMarzo A, Carducci M. The N-myc Down Regulated Gene1 (NDRG1) is a Rab4a Effector Involved in Vesicular Recycling of E-cadherin. PLoS One 2007; Sep 5;2 (9): e844.
  80. Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther. 2007; Jun 5; 6 (9). [Epub ahead of print].
  81. Carducci MA, Saad F, Abrahamsson P-A, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.  Cancer. 2007; 110: 1959-1966.
  82. Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC, Trock BJ.  The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.  J Urol 2008; 156-162.  Epub 2007 Nov 14.
  83. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M.  TGF-β signaling related markers in cancer patients with bone metastasis.  Biomarkers. 2008;13:217-236.
  84. Scher HI, Halabi S, Tannock IF, Morris MJ, Sternberg CN, Carducci MA, Eisenberger MA, Higano CS, Bubley GJ, Dreicer R, Petrylak DP, Kantoff PW, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.  Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2).  J Clin Oncol, 2008; 26: 1148-1159.
  85. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Jahisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ.  Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.  J Clin Oncol, 2008; 26: 1119-1127.
  86. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, Laille EJ, Besterman JM, Martell RE, Carducci MA.  A phase I study of MGCD0103 given as a three-times per week oral dose in patients with advanced solid tumors.  J Clin Oncol, 2008; 26: 1940-1947. 
  87. Hooker A, ten Tije AJ, Carducci M, Weber J, Garret-Mayer E, Gelderblom H, McGuire W, Verweij J, Karlsson M, Baker S.  Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P450 3A activity measurements.  Clin Pharmacol Ther, 2008; 84:111-118. Epub 2008 Jan 9. 
  88. Alumkal J, Carducci MA, Partin AW, Walsh PC, Herman JG.  Impact of DNA methylation on the identification of aggressive prostate cancer.  Urology, 2008; 72:1234-1239. Epub 2008 Apr 2. 
  89. Lassiter LK, Tummala MK, Hussain MH, Stadler WM, Petrylak DP, Carducci MA.  Phase II open label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have failed standard chemotherapy.  Clin Genitourinary Cancer, 2008; 6:31-35.  
  90. Snyder CF, Garrett-Mayer E, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW.  Symptoms, supportive care needs, and function in cancer patients: How are they related?  Qual Life Res, 2008; 17:665-677.  Epub 2008 May 21.   (NIHMS 283108)
  91. Bonfils C, Kalita A, Dubay M, Siu LL, Carducci MA, Reid G, Martell RE, Besterman JM, Li Z.  Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human, using a novel HDAC enzyme assay.  Clin Cancer Res, 2008;14: 3442-3449. (PMCID:282936)
  92. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A.  Pharmacogenetic pathway analysis of docetaxel elimination.   Clin Pharmacol Therap, 2008; 85:155-163.  Epub 2008 May 28. 
  93. Rathkopf D, Carducci MA, Morris M, Slovin S, Eisenberger M, Pili R, Denmeade S, Kelsen M, Curley T, Halter M, Collins C,  Fleisher M, Heller G,  Baker SD, Scher HI  Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.  J Clin Oncol 2008; 26: 2959-2965.  NIHMSID # 273871 
  94. O’Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenberg ML, Carducci M, Daly T, Adcock D, Lahn M. Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases.   Biologics; Targets and Therapy. 2008; 2: 563-569.
  95. Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H. Purpose and benefits of early phase cancer trials: What do oncologists say? What do patients hear?  J Empirical Res Human Res Ethics 2008; 3:57-68.
  96. Heath E, Hillman D, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot H, Tan W, Ivy P, Pili R, Carducci MA, Erlichman C, Liu G.  A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone refractory prostate cancer.  Clin Cancer Res, 2008, 14: 7940-7946.
  97. Nelson JB, Love W,  Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M.  Phase 3, randomized controlled trial of atrasentan in patients with nonmetastatic hormone refractory prostate cancer.  Cancer, 2008; 113: 2478-2487.
  98. Kortenhorst MSQ, Zahurak M, Shabbeer S, Kachhap S, Galloway N, Parmigiani G, Verheul HMW, Carducci MA.  A multiple loop, double cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.  Clin Cancer Res, 2008; 14: 6886-6894.
  99. Shabbeer S, Kumar-Anchoori R, Kachhap S, Davidson N, Carducci MA, Khan SR.  Fenugreek: A naturally occurring edible material as an anticancer agent.  Cancer Biol Ther 2009 Feb 18; 8 (3).  (PMCID:283130)
  100. Kortenhorst MSQ, Isharwal S, van Diest PJ, Chowdhury WH, Marlow C, Carducci MA, Rodriguez R, Veltri RW.  Valproic acid causes dose and time dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.  Mol Cancer Ther, 2009, 8:802-808.
  101. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.  Nat Med, 2009; 15: 559-565. [Epub 2009 Apr 12]
  102. Kass NE, Sugarman J, Medley AM, Fogarty LA, Taylor HA, Daugherty CK, Emerson MR, Goodman SN, Hlubocky FJ, Hurwitz HI, Carducci M, Goodwin-Landher A.  An intervention to improve cancer patients’ understanding of early-phase clinical trials.  IRB Ethics and Human Research 2009;31:1-10.
  103. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston D, Carducci MA, Choueiri TK, FIglin RA, Fishman M, Hancock SL Hudes GR, Jonasch R, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.   NCCN Clinical Proactice Guidelines in Oncology: Kidney Cancer.  J Natl Compr Canc Netw, 2009; 7: 618-630.
  104. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston D, Carducci MA, Choueiri TK, FIglin RA, Fishman M, Hancock SL Hudes GR, Jonasch R, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.  NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer.  J Natl Compr Canc Netw, 2009; 7: 672-693.
  105. Antonarakis ES, Heath EI, Walczak JR, Nelson WG, DeMarzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA.  A randomized, placebo controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: Evaluation of drug-specific biomarkers.  J Clin Oncol, 2009; 27:4986-4993. Epub 2009 Aug 31. 
  106. Lin J, Gilbert J, Rudek M, Zweibel J, Gore S, Jiemjit A, Zhao M, Baker S, Ambinder R, Herman J, Donehower R, Carducci MA.  A phase I dose finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.  Clin Cancer Res, 2009; 15: 6241-6249. Epub 2009 Sep 29.
  107. Snyder CF, Garrett-Mayer E, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Concordance of cancer patients’ function, symptoms, and supportive care needs. Qual Life Res, 2009; 18: 991-998.  Epub 2009 Aug 6
  108. Cetin K, Beebe-Dimmer J, Fryzek J, Markus R, Carducci MA.  Recent time trends in the epidemiology of stage IV prostate cancer in the United States: Analysis of data from the surveillance, epidemiology, and end results (SEER) program.  Urology, 2010; 75: 1396-1404. Epub 2009 Dec 6.
  109. Lin J, Sinibaldi WJ, Carducci MA, Denmeade S, Song D, Deweese T, Eisenberger MA.  Phase I trial with a combination of docetaxel and (153) Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.  Urol Oncol. 2011; 29: 670-675. Epub 2009 Dec 3.
  110. Snyder CF, Stein KB, Barone BB, Peairs KS, Yeh H-C, Derr RL, Wolff AC, Carducci MA, Brancati FL.  Does pre-existing diabetes affect prostate cancer prognosis? A systematic review.  Prostate Cancer Prostatic Diseases, 2010: 13:58-64. Epub 2009 Sep 1.
  111. Sharma P. Wisniewski A, Braga-Basaria M, Xu X, Yep M, Denmeade S, Dobs AS, Deweese T, Carducci M, Basaria S.  Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.  J Urol. 2009; 18:2265-2273.  Epub 2009 Sep 16.
  112. Diaz LA, Messersmith W, Sokoll L, Sinibaldi V, Moore S, Carducci M, Eisenberger M.  TNF-blockade in patients with advanced hormone refractory prostate cancer.  Invest New Drugs, 2011; 29: 192-194. Epub 2009 Oct 21.  (PMCID:282934)
  113. DiPaola RS, Chen Y-H, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth D, White E, Wilding G.  A randomized phaseII trial of mitoxantrone, estramustine and vinorelbine or Bcl-2 modulation with 13-cis-retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.   J Translational Med, 2010. 8:20.  (Open Access published 2/24/2010)
  114. Messersmith W. Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru D, Khan Y, Spira A, Dancey J, Iacobuzio-Donahue, Donehower R, Carducci M, Rudek M, Hidalgo M.  Phase I trial of oxaliplatin, infusional 5-fluoruracil, and leucovorin (FOLFOX-4) with erlotinib and bevacizumab in colorectal cancer.  Clin Colorectal Cancer, 2010; 9:297-304. [PMCID – 1852493]
  115. Snyder CF, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW.  Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: An illustration with the supportive care needs survey and the QLQ-C30.  Qual Life Res, 2010: 19:837-845. Epub 2010 Mar 26. 
  116. Snyder CF, Jensen RE, Geller G, Carducci MA, Wu AW.  Relevant content for a patient-reported outcomes questionnaire for use in oncology clinical practice: Putting doctors and patients on the same page.  Qual Life Res, 2010; 19: 1045-1055.   Epub 2010 Apr 29.
  117. Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood D, Creel P, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin A, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, DeMarzo AM, Carducci MA.  A pharmacodynamic study of rapamycin in men with intermediate to high risk localized prostate cancer. A Department of Defense Prostate Cancer Clinical Trials Consortium Trial.  Clin Cancer Res, 2010; 16: 3057-3066. [Epub 25 May]
  118. Resta L, Pili R, Eisenberger M, Spitz A, King S, Porter J, Franke A, Boinpally R, Carducci M, Sweeney C. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.  Cancer Chemother Pharmacol 2011; 67: 431-438. Epub 2010 May 6.  NIHMS275258
  119. Pratz KW, Cho E, Levis M, Karp JE, Gore SD, McDevitt M, Stine A, Zhao M, Baker SD, Carducci MA, Wright JJ, Rudek MA, Smith BD.  A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia, 2010; 24: 1437-1444.  Epub2010 Jun 10. 
  120. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MSQ, Wissing MD, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, Marchionni L, Lin J, Hoti N, Nortier JWR, DeWeese TL, Hammers H. Carducci MA.  Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor.  PLoSOne, 2010; 5 (6): e11208.  
  121. Snyder CF, Frick KD, Blackford AL, Herbert RJ, Neville BA, Carducci MA, Earle CC.  How does initial treatment choice affect short-term and long term costs for clinically localized prostate cancer? Cancer, 2010; 116: 5391-5399.  Epub 2010 Aug 23. 
  122. Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A.  Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.  J Clin Oncol, 2010; 28: 4562-4567. Epub 2010 Sep 20.
  123. Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, Kachhap S, Shim JS, Liu JO, Nelson WG, Yegnasubramanian S, Carducci MA.  Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.  Prostate, 2011; 71:333-343. Epub 2010 Aug 31. NIHMSID:  272155.
  124. Napora JK, Short RG, Muller DC, Carlson OD, Odetunde JO, Xu X, Carducci M, Travison TG, Maggio M, Egan JM, Basaria S.  High dose isoflavones do not improve metabolic and inflammatory parameters in androgen deprived men with prostate cancer. J Androl, 2011; 32: 40-48. Epub 2010 Aug 26. PMCID:30005077)
  125. Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M.  Lenalidomide in non-metastatic biochemically relapsed prostate cancer: Results of a phase I/II double blinded randomized study.  Clin Cancer Res, 2010; 16: 5269-5276.  Epub 2010 Oct 26.
  126. Sidana A, Wang M, Chowdury WH, Toubaji A, Shabbeer S, Netto GJ, Carducci MA, Lupold SE.  Rodriguez R. Does valproic acid induce neuroendocrine differentiation in prostate cancer? J Biomed Biotechnol 2010; 2011; article ID 607480 (10 pages). (Open access).
  127. Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, Agus D, Cooney K, Chen A, Smith DC, Hussain M.  Phase II study of cilengitide in patients with non-metastatic castration resistant prostate cancer, NCI-6735.  A study by the DOD/PCF prostate cancer clinical trials consortium.  Invest New Drugs. 2010; 30:749-757.  Epub 2010 Nov 4.
  128. Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NKE, Ching S, Gan J, Gottardis M, Obermeier MT, Reddy J, Zhang S, Vakkalagadda BJ, Wilding G, Scher HI.  Phase I dose-escalation study of the novel anti-androgen BMS-641988 in patients with castration-resistant prostate cancer.  Clin Cancer Res, 2011; 17: 880-887. Epub 2010 Dec 3. 
  129. Meyers, F, Carducci M, Loscalzo M, Linder J, Greasby T, Beckett L.  Effects of a problem-solving intervention (COPE) on quality of life for advanced cancer patients on clinical trials and their caregivers: Simultaneous Care Educational Intervention (SCEI): Linking palliation and clinical trials.  J Palliat Med. 2011; 14: 465-473.  Epub 2011 Mar 17. 
  130. Bruce JY, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, Treston A, Wilding G, Liu G.  A phase II study of 2-methoxyestradiol nanocrystal colloid dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs. 2012; 30:794-802. Epub 2010 Dec 22.
  131. Liu G, Chen, Y-H, Kolesar J, Huang W, DiPaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G.  Eastern Cooperative Oncology Group phase II trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.  Urol Oncol. 2013; 31:211-218.  Epub 2011 Jul 22.
  132. Yu EY, Massard C, Gross ME. Carducci M, Culine S, Hudes GR, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K.  Once daily dasatinib: Expansion of a phase 2 study evaluating the safety and efficacy of dasatinib in patients with metastatic castration resistant prostate cancer.  Urology, 2011; 77:1166-1171.
  133. Snyder CF, Blackford AL, Aaronson NK, Detmar SB, Carducci MA, Brundage MD, Wu AW.  Can patient-reported outcome measures identify cancer patients’ most bothersome issues? J Clin Oncol, 2011, 29: 1216-1220. Epub 2011 Feb 22.
  134. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized double-blind study.  Lancet, 2011; 377: 813-822.  Epub 2011 Feb 25.
  135. Keizman D, Huang P, Antonarakis E, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, Eisenberger MA.  The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.  Prostate, 2011; 71:1608-1615. Epub 2011 Mar 22. 
  136. Antonarakis E, Feng Z, Trock B, Humphreys E, Carducci MA, Partin AW, Walsh P, Eisenberger MA. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: long-term follow-up.  BJU Int, 2012; 109: 32-39. Epub 2011 Jul 20. 
  137. Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Carducci MA, Earle CC.  Preventive care in prostate cancer patients: Following diagnosis and for five-year survivors.  J Cancer Survivorship, 2011; 5: 283-291. Epub 2011 May 8.
  138. Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Hammers H, Carducci MA.  Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.  Europ J Cancer, 2011; 47: 1955-1961. Epub 2011 May 18. 
  139. Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES.  A non-comparative randomized phase II study of two doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemical recurrent hormone-naïve prostate cancer. Urol Oncol, 2011 Aug 2. [Epub ahead of print]  
  140. Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, DeMarzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers, H-J, Argani P, Reuter VE, Netto GJ.  Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.  Am J Surg Pathol, 2011; 35:1549-1556.  Epub 2011 Aug 29.
  141. Keizman D, Peng H, Carducci M, Eisenberger M.  Contemporary experience with ketoconazole in patients with metastatic castration resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate, 2012; 72: 461-467. Epub 2011 Jun 17. 
  142. Pili R, Haggman M, Stadler W, Gingrich J, Assikis V, Bjork A, Nordle O, Forsberg G, Carducci M, Armstrong A.  Phase II randomized double blind placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.  J Clin Oncol, 2011; 29:4022-4028. Epub 2011 Sep 19.
  143. Zabransky DJ, Smith HA, Thoburn Cj, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES.  Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.  Prostate, 2012; 72: 487-498. Epub 2011 Jul 11.
  144. Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA.  Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with non-hormonal agents: Combined analysis of 4 phase II trials.  Cancer, 2012; 118: 1533-1542.  Epub 2011 Aug 25.
  145. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA.  The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.  Europ J Cancer, 2012; 48: 202-208.  Epub 2011 Oct 19.   
  146. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB.  Kidney Cancer.  J Natl Compr Canc Netw. 2011; 9: 960-977. 
  147. Antonarakis E, Carducci M, Eisenberger M, Denmeade S, Slovin S, Jelaca-Maxwell K, Vincent M, Scher H, Morris M.  Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.  Cancer Chemot Pharmacol, 2012; 69:763-771. Epub 2011 Oct 22.
  148. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zweibel J, Carducci MA, Rudek MA. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis-retinoic acid in patients with solid tumors.  Brit J Cancer, 2012; 108: 77-84.  Epub 2011 Dec 1. 
  149. Kelly W, Halabi S, Carducci M, George D, Mahoney J, Stadler W, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang N, Small E.  A randomized double-blinded placebo controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with castration resistant prostate cancer (CALGB 90401).  J Clin Oncol, 2012; 30:1534-1540. Epub 2012 Mar 26.  
  150. Ellis L, Lehet K, Ramakrishnan S, Adelalye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterationis in microRNA expression.  PLoS One 2011; 6:e27178.  Epub 2011 Nov 7.
  151. Shabbeer S, Williams SA, Simons BW, Herman JG, Carducci MA.  Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence.  Cancer Prev Res, 2012; 5: 229-239. Epub 2011 Dec 2.
  152. Chaux A, Schultz L, Albadine R, Hicks J, Kim JJ, Allaf ME, Carducci MA, Rodriguez E, Hammers H-J, Argani P, Reuter V, Netto GJ.  Immnoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in papillary cell renal cell carcinomas.  Human Pathology, 2012; 43: 2129-2137. Epub 2012 Apr 26.
  153. Liu G, Chen-Y-H, DiPaola R, Carducci M, Wilding G.  Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): A trial of the Eastern Cooperative Group.  Clin Genitourin Cancer. 2012; 10: 99-105.  Epub 2012 Mar 1.  
  154.        

  155. Morris M, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrell J, Chudow J, Vincent M, Scher HI, Carducci MA.   A phase I/IIa study of AGS-PSCA for castration-resistant prostate cancer.  Annals Oncol. 2012; 23: 2714-2719. Epub 2012 May 2.  
  156. Keizman D, Ish-Shalom M, Pili R, Hammers H,Eisenberger MA, Boursi D, Berger R, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Carducci MA.  Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.  Eur J Cancer.  2012; 48:1031-1037. Epub 2012 Mar 10.
  157. Hughes EF, Wu AW, Carducci MA, Snyder CF.  What can I do? Recommendations for responding to issues identified by patient-reported outcomes assessments used in clinical practice.  J Supportive Oncol.  2012; 10: 143-148. Epub 2012 May 18.  
  158. Snyder CF, Blackford AL, Wolff AC, Carducci MA, Herman JM, Wu AW, PatientViewpoint Scientific Advisory Board.  Feasibility and Value of PatientViewpoint: A Web System for Patient-Reported Outcomes Assessment in Clinical Practice.  Psycho-Oncology. 2013; 22: 895-901. Epub 2012 Apr 30.
  159. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB.  Testicular cancer. J Natl Compr Canc Netw. 2012; 10: 502-535.
  160. Antonarakis E, Keizman D, Zhang,Z, Gurel D, Lotan T, Hicks J, Fedor H, Carducci M, DeMarzo A, Eisenberger M. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel following prostatectomy.  Cancer, 2012; 118: 6063-6071. Epub 2012 Jun 6.
  161. Paller CJ, Ye X, Wozniak PJ, Gillespie B, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA.  A randomized phase II study of pomegranate extract for men with rising prostate-specific antigen following initial therapy for localized prostate cancer.  Prostate Cancer Prostatic Dis, 2013; 16: 50-55. Epub 2012 Jun 12. 
  162. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA, Donehower RC, Zhao M, Rudek MA, Messersmith WA.  Phase I pharmacokinetics and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.  Invest New Drugs.  2013; 31:345-354.  Epub 2012 May 22.
  163. Goyal J. Nuhn P, Huang P, Tyagi P, Oh D, Carducci MA, Eisenberger MA, Antonarakis ES.  The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate Cancer.  BJU Int, 2012; 110: E575-582.  Epub 2012 Jun 15.
  164. Nwankwo N, Zhang Z, Wang T, Collins C, Resta L, Ermisch S, Day J, Decker R, kornberg L, Nicol S, Thornton D, Armstrong DK, Carducci MA.  Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: Safety, efficacy and pharmacokinetics.  Invest New Drugs. 2013; 31: 653-660. Epub 2012 Jul 6.
  165. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, DeMarzo A, Wilding G, Carducci MA, Dionne CA, Meller JV, Nissen P, Christensen SB, Isaacs JT.  Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.  Sci Transl Med. 2012 Jun 27;4: 140ra86.  {Epub ahead of Print]
  166. Cho SY, Gage KL, Mease R, Senthamizhchelvan S, Holt DP, Kwanisai-Jeffrey A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG.  Biodistribution, tumor detection and radiation dosimetry of 18F-DCFBC, a low molecular weight inhibitor of PSMA, in patients with metastatic prostate cancer.  J Nucl Med. 2012; 53: 1883-1891.  
  167. Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R.  Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotech 2012: Article ID 180363, 9 pages.
  168. Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A.  Pre-treatment neutrophil to lymphocyte ratio in metastatic castration resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram. Oncologist, 2012; 17:1508-1514. Epub 2012 Sep 12.
  169. Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA.  Repurposing itraconazole as a treatment for advanced prostate cancer: a non-comparative randomized phase 2 trial in men with metastatic castration-resistant prostate cancer.  The Oncologist. 2013; 18: 163-173.  Epub 2013 Jan 22.
  170. Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Wolff AC, Carducci MA, Earle CC.  Quality of care for comorbid conditions during the transition to survivorship: Differences between cancer survivors and non-cancer controls.  J Clin Oncol. 2013; 31: 1140-1148. Epub 2013 Feb 11.
  171. Kanarek NF, Kanarek M, Olatoye D, Carducci MA.  Removing barriers to participation in clinical trials: A conceptual framework and retrospective chart review study.  Trials, 2012; 13:237. [Epub ahead of print] 
  172. Antonarakis E, Heath E, Posadas E,  Yu E, Harrison M, Bruce J, Cho S, Wilding G, Fetterly G, Hangauer D, Kwan M-F, Dyster L, Carducci M.  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.  Cancer Chemother Pharmacol 2013; 71:883-892.   Epub 2013 Jan 13.
  173. Ryan CJ, Smith MR, deBono JS, Molina A, Logothetis CJ, deSouza P, Fizazi K, Mainwaring P, Puulast JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttman H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higanos CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA 303 Investigators/Collaborators (Carducci MA).  Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 366: 138-148.
  174. Snyder CF, Blackford AL, Okuyama T, Akech; T, Yamashita H, Toyama T, Carducci MA, Wu AW.  Using the EORTC QLQ-30 in clinical practice for patient management: Identifing scores requiring a clinician’s attention. Qual Life Res. 2013; 22:2685-2691.   Epub 2013 Mar 27. 
  175. Autio KA, Bennett AV, Jia X, Fruscione M, Beer TM, George DJ, Carducci MA, Logothetis CJ, Kane RC, Sit L, Rogak L, Morris MJ, Scher HI, Basch EM.  Prevalence of pain and analgesic use in a contemporary cohort of men with metastatic prostate cancer using patient reported outcomes.  J Oncol Practice 2013; 9: 223-229. Epub 2013 Jun 25.
  176. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney  JF,  Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ.  The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).  Cancer, 2013; 119:3636-3643.  Epub 2013 Jul 31.
  177. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci M, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. Docetaxel and atrasentan compared to docetaxel and placebo for men with advanced castration resistant prostate cancer: SWOG 0421.  Lancet Oncol. 2013; 14: 893-900. Epub 2013 Jul 17. 
  178. Wissing MD, Mendonca J, Kortenhorst MSQ, Kaelber N, Gonzalez M, Kim E, Hammers H, van Diest PJ, Carducci MA, Kacchap SK.  Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.  FASEB J.  2013; 27: 4279-4293.  Epub 2013 Jul 24. 
  179. Kortenhorst MSQ, Wissing MD, Rodriguez R, Kachhap SK, Jams JJM, Van der Groep P, Verheul HMW, Gupta A, Aiyetan PO, van der Wall E, Carducci MA, Van Diest PJ, Marchionni L.  Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.  Epigenetics. 2013; 8:907-920.  Epub 2013 Jul 19.  
  180. Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA.  Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.  Prostate Cancer Prostatic Dis. 2013; 16: 357-361. Aug 20. Epub 2103 Aug 20.   
  181. Fu C, van der Zwan A, Gerber S, Van Den Berg S, No E, Wang W, Sheibani N, Carducci MA, Kachhap S, Hammers HJ.  Screening assay for blood vessel maturation inhibitors.  Biochem Biophys Res Commun. 2013; 438:364-369. Epub 2013 Jul 25.
  182. Chaux A. Albadine R, Schultz L, Hicks J, Carducci MA, Argani P, Allaf M, Netto GJ.  Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.  Hum Pathol. 2013; 44:2323-2330.  Epub 2013 Aug 15.
  183. Freedland SJ, Carducci MA, Kroeger N, Partin AW, Rao J, Jin, Y, Kerkoutian S, Wu H, Li Y, Creel P, Mundy K, Gurganus R, Fedor H, King SA, Zhang Y, Heber D, Pantuck AJ.  A double blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer prior to radical prostatectomy. Cancer Prev Res. 2013; 6:1120-1127. Epub 2013 Aug 28. 
  184. Paller CJ, Olatoye D, Xie, S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner G.  The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014; 17:28-33.  Epub 2013 Oct 8. 
  185. Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle O, Forsberg G, Carducci MA, Pili, R.  Long term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013; 19: 6891-6901. Epub 2013 Nov 19.  
  186. Keizman D. Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, Berger R, Carducci MA.  Active smoking may negatively impact the response rate, progression free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.  The Oncologist. 2014; 19:51-60.  Epub 2013 Dec 5.
  187. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Bhala N, Emberson J, Merhi A, Abrmson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennenkens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. (Carducci MA-Collaborator) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analysis of individual participant data from randomised trials. Lancet. 2013; 382: 769-779.  Epub 2013 May 30. 
  188. Nuhn P, Vaghasia A, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, Antonarakis ES.  Association of pretreatment neutrophil-to-lymphocyte ratio and overall survival in patients with metastatic castration-resistant prostate cancer treated with first-line docetaxel.  BJU Int.2014; 114:E11-17.  Epub 2013 Oct 29.
  189. Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin C-C. Mahoney J, Modi S, Lee P, Ernstoff MS, Su-W-C, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA. An open-label, single-arm phase II trial of the polo-like kinase inhibitor volasertib (BI6727) in patients with locally advanced or metastatic urothelial cancer.  Cancer. 2014; 120: 976-982.  Epub 2013 Dec 11.
  190. Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D.  Comparison of abiraterone versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.  The Prostate. 2014; 74: 433-440.  Epub 2013 Dec 11.   
  191. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk III, Datar RH, Garzotto M, Mack PC, Lara Jr, P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.   J Clin Oncol.  2014; 32: 1136-1142. Epub 2014 Mar 10.  
  192. Sausville E, LoRusso P, Carducci M, Carter J, Quinn MF, Malburg L, Azad N, Cosgrove D, Knight R, Barker P, Zabludoff S, Agbo F, Oakes P, Senderowicz A.  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol, 2014; 73:539-549. Epub 2014 Jan 22.
  193. Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES.  The effect of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.  Eur Urol. 2014; 66: 646-652.  Epub 2014 Jan 24.
  194. Gonzalez-Roibon N, Faraj SF, Kim J, Chaux A, Munari E, Ellis C, Sharma R, Bivalacqua TJ, Schoenberg M, Carducci M, Netto GJ.  IGF1R overexpression predicts outcome in invasive urothelial carcinoma of the urinary bladder.  Urology. 2014; 83:1444 e 1-6. Epub 2014 Apr 6.  
  195. Pollack CE, Frick KD, Herbert RJ, Blackford AL, Neville BA, Wolff AC, Carducci MA, Earle CC, Snyder CF. It’s who you know: patient-sharing, quality, and costs of cancer survivorship care.  J Cancer Surviv. 2014; 8: 156-166.  Epub 2014 Feb 28.
  196. Snyder CF, Herman JM, White SM, Luber BS, Blackford AL, Carducci MA, Wu AW.  When using patient-reported outcomes in clinical practice, the measure matters: A randomized controlled trial.  J Oncol Pract. 2014; 10:e299-306.   Epub 2014 Jul 1. 
  197. Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, Refici-Buhr M, Chyla B, Shepherd SP, Giranda WL, Alumkal JJ.  Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.  Invest New Drugs.  2014; 32:904-912. Epub 2014 Apr 26.
  198. Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kolmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ.  A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014; 32:1005-1016.  Epub 2014 May 5.
  199. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Wooten T, Rumble RB, Dusetzina SB, Virgo K. Systemic therapy in men with metastatic castration-resistant prostate cancer (CRPC): American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guidelines.  J Clin Oncol, 2014; 32:3436-3448. Epub 2014 Sep 8.
  200. Paller C, Wissing M, Mendonca J, Sharma A, Kim E, Kim H-S, Kortenhorst M, Gerber S, Rosen M, Shaikh F, Zahurak M, Rudek M, Hammers H, Rudin C, Carducci MA, Kachhap S.  Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.  Cancer Med. 2014; 3: 1322-1235.  Epub 2014 Jul 3.
  201. Pili R, Carducci M, Brown P, Hurwitz H.  An open-label study to determine the maximum toleraed dose of the kinase inhibitor CEP-11981 in patients with advanced cancer.  Invest New Drugs, 2014; 32:1258-1268.  Epub 2014 Aug 26.
  202. Mendonca J, Sharma A, Kim H-S, Hammers H-J, Meeker A, DeMarzo A, Carducci M, Kauffman M, Sharon, Kachhap S.  Selective inhibitors on nuclear export (SINE) and novel therapeutics for prostate cancer.  Oncotarget, 2014; 5: 6102-6112. 
  203. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, DeMarzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.  New Engl J Med. 2014; 371: 1028-1038.   Epub 2014 Sep 3. 
  204. Armstrong AJ, Kaboteh R, Carducci MA, Damber J-E, Stadler WM, Hansen M, Edenbrandt L, Forsberg G, Nordle O, Pili R, Morris MJ.  Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol.  2014; 32:1308-1316.  Epub 2014 Sep 15.
  205. Goldkorn A, Ely B, Tangen CM, Tai Y-C, Xu T, Li H, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk III, JP, Garzotto M, Mack PC, Lara Jr, P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI.  Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase 3 metastatic castration prostate cancer trial. Int J Cancer. 2015; 136:1856-1862.  Epub 2014 Sep 13.
  206. Lin J, Zhang T, Duffy D, Hoffman-Censits, Kilpatrick D, Trabulsi E, Lallas C, Chervoneva I, Limentant K, Kennedy B, Kessler S, Gomella L, Force T, Antonarakis ES, Carducci MA, Force T, Kelly WK.  A pilot phase II study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.  Am J Cancer Ther Pharmacol. 2014; 2:21-32.  
  207. Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES  Clinical activity of enzalutamide in docetaxel-naïve and docetaxel pre-treated patients with metastatic castration-resistant prostate cancer.  Prostate. 2014; 74: 1560-1568.  Epub 2014 Aug 31.
  208. Patel JN, Jiamg C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Kelley M, Morris MJ, Kelly WK, McLeod HL.  Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration resistant prostate cancer patients treated on CALGB 90401 (ALLIANCE).  Cancer. 2015; 121:1025-1031.  Epub 2014 Nov 21. 
  209. Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris III, HA, Carducci MA, Dicker AP, Gonen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LE.  American Society of Clinical Oncology Policy Statement Update: The critical role of phase 1 trials in cancer research and treatment.  J Clin Oncol. 2014; 33:278-284.  Epub 2014 Dec 15. 
  210. Azaro A, Rodon J, Carducci M, Sepulveda-Sanchez JM, Gueorguieva I, Cleverly AL, Desaiah D, Namaseevayam SP, Holdhoff M, Lahn MM.  Case series of cancer patients treated with galunisertib, a transforming growth factor-beta receptor 1 kinase inhibitor in a first-in-human dose study.  J Med Cases. 2014; 5:603-809.
  211. Snyder CF, Blackford AL, Sussman J, Brainbridge D, Howell D, Seow H, Carducci M, Wu AW.  Identifying change scores on the EORTC-QLQ-C30 representing a change in patients’ supportive care needs.  Qual Life Res. 2015; 24:1207-1216.  Epub 2014 Nov 15.   
  212. Rodon J, Carducci MA, Speulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly AL, Sokalingum Pillay N, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakely J, Lahn MM, Baselga J. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 in patients with advanced cancer and glioma.  Clin Cancer Res. 2015; 21: 553-560. Epub 2014 Nov 25.
  213. Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Qudard S, Karsh L, Carducci M, Damiao R, Wang H, Ying W, Goessl C. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostae cancer. Eur Urol. 2015; 68:42-50.  Epub 2014 Oct 29.
  214. DiPaola RS, Chen Y-H, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley J, Arlen PM, Butterfield LH, Wilding G.  A national multicenter phase II study of PSA pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.  Eur Urol. 2015; 68:365-371.  Epub 2014 Dec 18. 
  215. Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration –resistant prostate cancer: Results from a pilot clinical study.  Sci Transl Med. 2015; 7: 269ra2.
  216. Kovacs RJ, Maldonado G, Azaro A, Fernandez MS, Romero FL, Sepulveda-Sanchez JM, Corretti M, Carducci M, Dolan M, Gueorguieva I, Cleverly AL, Pillay NS, Baselga J, Lahn MM.  Cardiac safety of TGF-β receptor kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study. Cardiovasc Toxicol. 2015; 15:309-323. Epub 2014 Dec 9.
  217. Rodon J, Carducci M, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakely J, Lahn MM, Baselga J. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.  Invest New Drugs. 2015; 33:357-370.  Epub 2014 Dec 23.
  218. Keizman D, Rouvinov K, Sella A, Gottfried M, Maimon N, Kim JJ, Eisenberger MA, Sinibaldi V, Peer A, Carducci MA, Mermershtain W, Leibowitz-Amit R, Weitzen R, Berger R.  Is there a “trial effect” on outcome of patients with metastatic renal cell carcinoma treated with sunitinib?  Cancer Res Treat. 2016; 48:281-287. Epub 2015 Mar 5.
  219. Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Lemke KW, Carducci MA, Wolff AC, Earle CC. Comorbid condition care quality in cancer survivors: Role of primary care and specialty providers and care coordination. J Cancer Surviv. 2015; 9:641-649. Epub 2015 Feb 26.  
  220. Paller CJ, Rudek MA, Zhou XC, Wagner WD, hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA.  A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.  Prostate. 201; 75:1518-1525.  Epub 2015 May 27.
  221. Antonarakis. ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.  Androgen receptor splice variant-7, AR-V7, and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.  JAMA Oncol. 2015; 1:582-591.  Epub 2015 Jun 4. 
  222. Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong Y-N, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS.  Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. NEJM. 2015; 373:737-746.  Epub 2015 Aug 5.
  223. McNeel DG, Chen Y-H, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial fo the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother. 2015; 11: 2469-2474. Epub 2015 Jun 25.
  224. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.  Ann Oncol. 2015; 26: 1859-1865.  Epub 2015 Jun 17.
  225. Carducci MA, Manola J, Nair SG, Liu G, Rousey S, Dutcher JP, Wilding G. Atrasentan in patients with advanced renal cell carcinoma: A phase II trial of the ECOG-ACRIN Cancer Research Group (E6800). Clin Genitourin Cancer. 2015; 13:531-539.  Epub 2015 Jul 17. 
  226. Stopeck AT, Fizazi K, Body J-J, Brown JE, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.  Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.  Support Care Cancer. 2016: 24: 447-455.  Epub 2015 Sep 3.
  227. Armstrong AJ, Halabi S, Healy P, Lee WR, Koontz BF, Moul JW, Mundy K, Creel P,Wood D, Davis K, Carducci MA, Stein M, Hobbs C, Reimer B, Nguyen M, Anand M, Bratt L, Kim S, Tran PT, George DJ. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis. 2016; 19: 100-106.  Epub 2016 Jan 12. 
  228. Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis E, Eisenberger M, Carducci M, Ross A, Kantoff P, Hold P, Dannals RF, Mease RC, Pomper MG, Cho SY.  Comparison of PSMA-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-sensitive and castration-resistant metastatic prostate cancer. J Nucl Med. 2016; 57:46-53.  Epub 2015 Oct 22.
  229. Scher HI, Morris MJ, Stadler WM, Higano CS, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis CJ, Nanus DM, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson P, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ.  Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3.  J Clin Oncol. 2016; 34: 1402-1418.  Epub 2016 Feb 22. 
  230. Park JC, Gandhi NM, Carducci MA, Eisenberger MA, Baras AS, Netto GJ, Liu J-J, Drake CG, Schoenberg MP, Bivalacqua TJ, Hahn NM. A retrospective analysis of the effect of time from diagnosis to cystectomy on survival in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy.  J Urol. 2016; 195: 880-885. Epub 2015 Nov 17.  
  231. Wu AW, White SM, Blackford AL, Wolff AC, Carducci MA, Herman JM, Snyder CF, PatientViewpoint Scientific Advisory Board. Improving an electronic system for measuring PROs in routine oncology practice. J Cancer Surviv. 2016; 10:573-582.  Epub 2015 Dec 7.
  232. Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. Prostate 2016; 76: 512-520.  Epub 2015 Dec 22.
  233. McKay R, Zurita AJ, Werner L, Bruce J, Carducci M, Stein M, Heath E, Hussain A, Tran H, Sweeney CJ, Ross R, Kantoff P, Slovin S, Taplin ME.  A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy.  J Clin Oncol. 2016:34:1913-1920.  Epub 2016 Apr 4. 
  234. Haas N, Manola J, Uzzo RG, Flaherty KT,  Woog CG,  Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Luzel TM, Sexton WJ, Wong Y-N, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, Dipaola RS.  Adjuvant therapy for high-risk kidney cancer: ECOG-ACRIN E2805.  Lancet. 2016; 387:2008-2016.   Epub 2016 Mar 8. 
  235. Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bogemann M, Hutson T, Milecki P, Cowdhury S, Gallardo E, Schwartsmann G, Pouget J-C, Baton F, Nederman T, Tuvesson H, Carducci M. Phase III randomized, double-blind, placebo-controlled study of tasquinimod in men with metastatic castration-resistant prostate cancer.  J Clin Oncol. 2016; 34: 2636-2643.  Epub 2016 Jun 13. 
  236. Keizman D, Sarid D, Lee JL, Sella A, Gottfried M, Hammers H, Eisenberger MA, Carducci MA, Sinibaldi V, Neiiman V, Rosenbaum E, Peer A, Neumann A, Mermershtain W, Rouvinov K, Berger R, Yildiz I.  Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib.  Oncologist, 2016; 10: 1212-1217.  Epub 2016 Jul 5. 
  237. Frick KD, Snyder CF, Herbert RJ, Blackford Al, Neville BA, Wolff AC, Carducci MA, Earle CC.  The relationship between quality of comorbid condition care and costs for cancer survivors.  J Oncol Pract. 2016:12:e734-745. Epub 2016 May 10.   
  238. Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z,  Pomper MG, Cho SY.  PSMA-based [18F ]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer.  Mol Imaging Biol. 2016; 18: 411-419. Epub 2016 Apr 14.
  239. Keizman D, Ish Shalom I-S, Sella A, Gottfried M, Maimon N, Peer A, Hammers H, Eisenberger MA, Sinibaldi V, Neiman V, Rosenbaum E, Sarid D, Mermershtain W, Rouvinov K, Berger R, Carducci MA.  Metformin use and outcome of sunitinib treatment in patients with diabetes and metastatic renal carcinoma.  Clin Genitourin Cancer.  2016; 14: 420-425.  Epub 2016 Apr 27.  
  240. Mahalingam D, Wilding G.  Denmeade S, Sarantopoulas J, Consgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE, Carducci M. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase 1 clinical trial in patients with refractory, advanced, or metastatic solid tumors.  Br J Cancer. 2016; 114:986-994. 
  241. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Keley MJ, Nakamura Y, Kubo M, Dorsey SG, Dola ME, Morris MJ, Ratain MJ, McLeod HL. Pharacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy.  Clin Cancer Res. 2016; 22:4890- 4900.  Epub 2016 May 3.
  242. Paller CJ, Denmeade SR, Carducci MA.  Challenges of conducting clinical trials of natural products to combat cancer.  Clin Advances in Hematology and Oncology.  2016; 14:447-455.
  243. Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, Paller C, Denmeader SR.  Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: Results from the phase II BATMAN study.  Prostate. 2016; 76:2636-2643.  Epub 2016 Jun 13.
  244. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimao MP, Klinedinst MA. Psilocybin produces substantial and sustaned decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.  J Psychopharmacol. 2016; 30:1181-1197.  
  245. Tran PT, Radwan N, Ross AE, Reyes D, Wright JL, Song D, Deville C Jr, DeWeese TL, Carducci M, Schaeffer EM, Pienta K, Eisenberger M.  Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.  Int J Radiat Oncol Biol Phys. 2016; 96:E248.
  246. Weber J, Levit L, Adamson P, Bruinooge S, Burris H, Carducci M, Dicker A, Gonen M, Keefe S, Postow M, Thompson M, Waterhouse D, Weiner S, Schuchter L. Reaffirming and clarifying the American Society of Clinical Oncology’s statement on the critical role of phase 1 trials in cancer research and treatment.  J Clin Oncol, 2017; 35: 139-140.  Epub 2016 Nov 28. 
  247. Goldstein A, Valda Toro P, Lee J, Silberstein J, Nakazawa M, Waters I, Cravero K Chu D, Cochran R, Kim M, Shinn D, Torquato S, Hughes R, Carducci MA, Paller CJ,  Denmeade SR,, Kressel B, Trock BJ, Eisenberger MA, Antonarakis ES, Park BH, Hurley PJ.  Detection fidelity of AR mutations in plasma derived cell-free DNA.  Oncotarget 2017; 8:15651-15662. Epub 2017 Jan 31.
  248. Bernard D, Muralidhar V, Chen Y-H, Sridhar SS, Mitchel E, Pettaway CA, Hays E, Carducci M, Nguyen PL, Sweeney CJ. Impact of ethnicity on the outcomes of men with metastatic hormone-sensitive prostate cancer. Cancer 2017; 123:1536-1544.  Epub 2017 Jan 5. 
  249. Na R, Zheng Sl, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth Dl Jr. Quinn M, Humphries E, Wiley KE, Isaacs SD, Wu Y. Liu X, Zhang N, Wang CH, Khandekar J, Hulick PJ, Shevrin DH, Cooney KA, Shen Z, Partin AW, Carter HB, Carducci MA, Eisenberger MA, Denmeade SR, McGuire M, Walsh PC, Helfand BT, Brendler CB, Ding Q, Xu J, Isaacs, WB. Germline mutations in ATM and BRCA 1 /2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.  Eur Urol. 2017; 7: 740-747.  Epub 2016 Dec 9.
  250. Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge M, Wahl R, Martin J, Mile K, Paesante S, Adelaiye R, Godoy A, King S, Zweibel J, Carducci M.  Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear cell renal cell carcinoma: a multicenter, single arm Phase I/II clinical trial.  Br J Cancer.  2017; 116: 874-883.  Epub 2017 Feb 21.
  251. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Shu Y, Silberstein J, Taylor M, Maughan B, Denmeade SR, Pienta KJ, Paller C, Carducci MA, Eisenberger MA, Luo J.  Clinical significance of AR-V7 mRNA detection in circulating tumor cells of men with metastatic castration resistant prostate cancer treated with first- and second line abiraterone and enzalutamide.  J Clin Oncol 2017; 35:2149-2156.  Epub 2017 Apr 6.
  252. Virgo K, Basch E, Loblaw D, Oliver T, Rumble RB, Carducci M, Nordquist L, Taplin ME, Winquist E, Bacher A, Singer E.  Second-line hormonal therapy for men with chemotherapy-naïve castration-resistant prostate cancer (CRPC):  American Society of Clinical Oncology Provisional Clinical Options. J Clin Oncol 2017; 35: 1952-1964.  Epub 2017 Apr 25. 
  253. Pili R, Jegede O, Carducci MA, Manola J, Groteluschen DL, Appleman LL, Liu G, Shanks JC, Dakhil SR, Dutcher J, DiPaola RS.  A randomized phase II study to determine the effect of 2 different doses of AVE0005 (VEGF Trap) in patients with metastatic renal cell carcinoma (E4805).  Clin Genito Cancer.  2017 Apr 26.  [Epub ahead of print]
  254. Sharma A, Mendonca J, Ying J, Kim H-S, Verdone J, Zarif J, Carducci MA, Hammers H, Pienta KJ, Kachhap SK. The prostate metastasis suppressor gene NDRG1 differentially regulated cell motility and invasion.  Molec Oncol.  2017; 11: 655-669.  Epub 2017 Apr 2.
  255. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain M, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuisen PJ, Agarwal N, Carducci MA, Monk P, Quinn DI. Validation of the associaion of RECIST changes with survival in men with metastatic castration resistant prostate cancer treated on SWOG 0421.  Clin Genitourin Cancer. 2017; 15:635-641. Epub 2017 May 10.  
  256. Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA.  Immunomodulation by entinostat in renal cell carcinoma patients receiving high dose interleukin 2: a multicenter, single-arm, phase 1 /2 trial (NCI-CTEP#7870).  Clin Cancer Res. 2017; 23:7199-7208. Epub 2017 Sep 22.  
  257. Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta K, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatis prostate CancEr  (ORIOLE).  BMC Cancer 2017; 17:453.  
  258. Paller CJ, Cole AP, Partin AW, Carducci MA, Kanarek NF.  Risk factors for metastatic prostate cancer: A sentinel event case series.  The Prostate.  2017; 77: 1366-1372.  Epub 2017 Aug 8.
  259. Wong Y-N, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams Sd, Fisch MJ, Cella D, Carducci MA, Wilding G.  Phase 2 study of weekly paclitaxel by 1-HR infusion plus estramustine in metastatic hormone-refractory prostate cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1898).  Clin Genitourin Cancer, 2018; 16: e315-e322.  Epub 2017 Oct 16.  
  260. Armstrong AJ, Antonarakiz ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut W, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreic A, Mottet N, Gleave M, Morris MJ, Scher HI. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.  Ann Oncol. 2017 Oct 23. [Epub ahead of print] 
  261. Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi W, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeader SR.  Bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer and progression on androgen receptor-directed therapy: results from the post-enzalutamide cohort of a multi-cohort, open label, phase 2 trial.  Lancet Oncol, 2018; 19:76-86.  Epub 2017 Dec 13. 
  262. Paller C, Zhou X, Heath E, Taplin ME, Mayer T, Stein M, Bubley G, Pili R, Hudson T, Kakaria R, Abbas M, Anders N, Dowling D, King S, Brunds A, Wagner W, Drake C, Antonarakis E, Eisenberger M, Denmeade S, Rudek M, Rosner G, Carducci M.   Muscadine grape skin extract in men with biochemically recurrent prostate cancer: A randomized, multicenter, placebo-controlled clinical trial.  Clin Cancer Res. 2018; 24: 306-315. Epub 2017 Nov 7.   
  263. Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ.  Prostate-specific antigen nadir is prognostic in metastatic hormone sensitive prostate cancer treated with androgen deprivation with or without docetaxel.  J Clin Oncol, 2018; 36: 376-382. Epub 2017 Dec 20. 
  264. Eggly S, Hamel LM, Heath E, Manning M, Albrecht T, Barton E, Wojda M, Foser T, Carducci M, Lansey D, Wang T, Abdallah R, Abrahmian N, Kim S, Seneft N, Penner L.  Partnering around cancer clinical trials (PACCT): Study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials.  BMC Cancer 2017, 17:807-819.  Epub 2017 Dec 2.
  265. Kyriakopoulos C, Chen Y-H, Carducci M, Liu G, Jarrard D, Hahn N, Shevrin D, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack E, Vogelzang N, Picus, Cooney M, Garcia J, DiPaola R, Sweeney C.  Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805:CHAARTED trial.  J Clin Oncol, 2018:36: 1080-1087. Epub 2018 Jan 31.  
  266. Morgans AK, Chen Y-H, Sweeney C, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS< Patrick-Miller LJ.  Quality of life (QOL) during tretment with chemohormonal therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in prostate cancer (CHAARTED).  J Clin Oncol, 2018; 36:1088-1095.  Epub 2018 Mar 9.
  267. Gravis G, Boher J-M, Chen Y-H, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger M, Habibian M, Dreice R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Burden of metastatic castrate naïve prostate cancer patients, to identify men more likely to benefit from early docetaxel: furher analyses of CHAARTED and GETUG-AFU 15 studies.  Europ Urol, 2018; 73:847-855.  Epub 2018 Feb 20.
  268. Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A. Widmark A, Sternberg CN, Pili R, Tuvesson H, Nordle O, Carducci M, Morris MJ. Phase 3 validation of the automated Bone Scan Index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer.  JAMA Oncol, 2018; 4:944-951.    Epub 2018 May 17.   
  269. Stein MN, Chen Y-H, Carducci MA, Hudes GR, Lerma PM, Tan WW, Kugler JW, Dalune R, Rowland KM, Kuzel TM, DiPaola RS.  Phase II trial of E7389 (Halichondrin D Analog) in patients with metastatic hormone refractory prostate cancer: A trial of the ECOG-ACRIN Cancer Research Group (E5805).  Am J Clin Oncol. 2019; 42:375-381.  Epub 2019 Feb 15.
  270. Motzer RJ, Tannier NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salaman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda D, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate 214 Investigators (Carducci MA).  Nivolumab plus ipilumimab versus sunitinib in advanced renal cell carcinoma.  N Engl J Med. 2018; 378:1277-1290.  Epub 2018 Mar 21
  271. Boudadi K, Suzman D, AnagnostouV, Fu W, Luber B, Wang H, Niknafs N, White J, Silberstein J, Sullivan R, Dowling D, Harb R, Nischl T, Veeneman D, Tomlins S, Wang Y, Jendrisak A, Graf R, Dittamore R, Carducci M, Eisenberger M, Haffner, M, Meeker M, Esleman J, Luo J, Velculescu V, Drake C, Antonarakis E.  Ipilumimab plus nivolumab and DNA-repair defects in AR-V7- expressing metastatic prostate cancer.  Oncotarget, 2018; 9: 28561-28571.  Epub 2018 Jun 19. 
  272. Lara PN, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI.  Bone turnover biomarkers identify unique prognostic risk groups in men with castartion resistant prostate cancer and skeletal metastases: Results from SWOG 0421.  Cancer Treat Res Commun. 2018; 16:18-13. 
  273.  Carducci M, Shaheen M, Markman D, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J.  A phase 1, first-in-human study of AMG900, an orally administered pan-aurora kinase inhibitor, in adult patients with advanced solid tumors.  Invest New Drugs. 2018; 36:1060-1071.  Epub 2018 Jul 7.   
  274. Unger JM, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL, Vogelzang NJ, Thompson IM, Moinpour CM.  Patient- reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and atrasentatn versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes 2018 Jun 13: 2:27.   [Epub ahead of print]
  275. Kanarek N, Lansey D, Agbahiwe H, Fashoyin-Aje L, Hardesty J, Olatoye D, Wolff AC, Stearns V, Jaffee L, Carducci M, Zellars R.  Why do few cancer patients enroll into clinical trials? Curr Trends Clin Trials. 2018 Jul11,  [Epub ahead of print]
  276. Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M. Schaeffer EM, Pienta KJ, Eisenberger M, Tran PT.  Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World J Urol. 2018 Sep 6.  [Epub ahead of print]
  277. Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Vosss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.  Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.  J ImmunoTherapy Cancer.  2018:6:109. Epub 2018 Oct 22.
  278. Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SP, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.  Efficacyof Radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects. Eur Urol 2018 Oct 4.  [Epub ahead of print]
  279. Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC.  Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.  J Immunother Cancer 2018; 6: 105.   Epub 2018 Oct 11.
  280. McDermott DF, Carducci M.  Progress in kidney cancer outcomes through collaboration, innovatin, and discovery.  J Clin Oncol. 2018;36: 3529-3532.  Epub 2018 Oct 29. 
  281.  Ignacio DN, Mason KD, Hackett-Morton EC, Albanese C, Ringer L, Wagner WD, Wang PC, Carducci MA, Kachhap SK, Paller CJ, Mendonca J, Chan LL-Y, Lin B, Hartle DK, Green JE, Brown CA, Hudson TS.   Muscadine grape skin extract inhibits prostate cancer cells by inducing cell-cycle arrest and decreasing migration through heat shock protein 40.  Heliyon, 2019; 5: e01128 (published on line). 
  282. Tepley BA, Qiu F, Antonarakis ES, Carducci MA, Denmeader SR. Risk of development of visceral metastases subsequent to abiraterone vs placebo: an analysis of mode of radiographic progression in COU-AA-302. Prostate 2019; 79: 929-933. 
  283. Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG.  Predicting renal cancer recurrence: Defining limitations of existing prognostic nodels with prospective trial based validation.  J Clin Oncol, 2019;37: 2062-2071.  Epub 2019 Jun 19.  
  284. Torquato S, Pallawajjala A, Goldstein A, Valda Toro P, Silberstein JL, Lee, J, Nakazawa M, Waters I, Chu D, Shinn D, Groginski T, Hughes RM, Simons BW, Khan H, Feng Z, Carducci MA, Paller CJ, Denmeader SR, Kressel B, Eisenberger MA, Antonarakis ES, Trock BJ, Park BH, Hurley PJ.  Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer.  JCO Precis Oncol.  2019:3.   Epub 2019 April 3.
  285. Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DYC, Lara PN, Choueiri TK, Maskens D< Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signorette S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol 2019; 15: 1683-1695. Epub 2019 Apr 9.
  286. Paller CJ, Huang EP, Luechtefeld T, Massett HA. Williams CC, Zhao J, Gravell AE, Tamashiro T, Reeves S, Rosner GL, Carducci MA, Rubinstein L, Ivy SP. Factors affecting combination trial success (FACTS): Investigator survey results on early-phase combination trials.  FrontMed. 2019;6(122): 1-11. [Epub 2019 June 4]
  287. Meyer AR, Carducci MA, Denmeade SR, Markowski MC, Pomper MG, Pierorazio PM, Allaf MR< Rowe SP, Gorin MA. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET.CT. Ann Nucl Med. 2019 May 30 [Epub ahead of print]
  288. Issaacson Vehlo P, Lim D, wang H, Kaur HB, Almutairi F, Carducci MA, Denmeader SR, Markowski MC, Isaacs WB, Antonarakis ES, Pritchard CC, Eisenberger MA< Lotan TL. Molecular characterization and clinical outcomes of primary Gleason score 5 prostate cancer after radical prostatectomy.  JCO Precis Oncol. 2019, jul 26.
  289. Isaacsson Wehlo P, Fu W< Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA, Antonarakis ES.. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur Urol. 2019;19:30439-7.  Epub 2019 Jun 5.
  290. Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denmeade S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer Tm, DeWeese TL, Hearn JW, Greco S, DeVille C, Desai NB, health EI, Liauw S, Spratt DE, hung AY, Antonarakis ES, Tran PT.  A phse II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo wersus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).  BMC Cancer. 2019;19: 572-582.
  291. Shenderov E, Isaacson Vehlo P, Awan AH, Wang H, Mirkheshti N, Lotan TL, Carducci MA, Pardoll DM, Eisenberger MA, Antonarakis ES. Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. The Prostate. 2019;79: 1572-1579. Epub 2019 Aug 7.
  292. VanderWeele DJ, Antonarakis ES, Carducci M, Dreicer R, Fizazi K, Gillesen S, Higano CS, Morgans AK, Petrylak DO, Sweeney CJ, Hussain M. Metastatic hormone sensitive prostate cancer: Clinical decision making in a rapidly evolving landscape of life prolonging therapy. J Clin Oncol. 2019, in press. 
  293. Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S, DeWeese TL, Antonarakis ES, Markowski M, Paller C, Denmeader S, Carducci M, Walsh PC, Peinta KJ, Eisenberger M, Tran PT.  Radiotherapy in the definitive management of oligometastatic prostate cancer: The Johns Hopkins Experience. Int J Radiat Oncol Biol Phys. 2019 Aug 13. [Epub ahead of print]
  294. Motzer RJ, Rini BI, McDermott DF, Aren Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinch B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthelemy P, Leibowitz-Amit R, Plimack ER, Oosling SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DTC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grunwald V, McHenry MB, Mekan S, Tannier NM. Nivolumab plus ipilumimab versus sunitinib in first line treatment for advanced renal cell carcinoma: estended follow-up of efficacy and safety results from a radnomised, controlled, phase 3 trial. Lancet Oncol. 2019 Aug 16. [Epub ahead of print]

Review Articles

 

  1. Eisenberger M, Reyno L, Sinibaldi V, Sridhara R, Carducci M, Egorin M.  The experience with Suramin in advanced prostate cancer.  Cancer 1995; 75: 1927-1934.
  2. Carducci MA, DeWeese TL, Nelson WG, Simons JW, Sinibaldi V, Eisenberger MA.  Prostate cancer treatment strategies based on tumor-specific biological principles: Future directions.  Seminars in Oncology, 1996; 23(6):56-62.
  3. Carducci MA.  Differentiation as a therapeutic target. Cancer Research Therapy and Control.  1998; 7: 2443-2446.
  4. Carducci MA, DeWeese TL, Nelson JB.  PSA and other markers of therapeutic response. Urologic Clinics of North America. 1999; 26:291-302.
  5. Laufer M, Carducci MA, Blumenstein B, Eisenberger MA.  Combined androgen blockade (CAB) for the treatment of patients with metastatic prostatic cancer: Summary of 15 years of Clinical Research. AUA Update Series. 1999; 18(29):226-231.
  6. Nelson JB, Carducci MA.  The role of the endothelin axis in prostate cancer.  The Prostate Journal. 1999; 1(3):126-130.
  7. Nelson JB, Carducci MA, The role of small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer.  Cancer Investigation.  2000; 18: 87 – 96.
  8. Wood HM, Carducci MA.  Differentiation therapy for prostate cancer:  The Prostate Journal, 2000; 2: 6-13.
  9. Laufer M, Pound CR, Carducci MA, Eisenberger MA.  Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology. 2000; 55: 309-315.
  10. Nelson JB, Carducci MA.  The role of endothelin-1 and and endothelin receptor antagonists in prostate cancer.  Br J Urol. 2000; 85(2): 45-48.
  11. Laufer M, Denmeade S, Sinibaldi V, Carducci M, Eisenberger MA.  Complete androgen blockade for prostate cancer:  What went wrong.  J Urol. 2000; 164: 3-9.
  12. Gore SD, Carducci MA.  Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetlase inhibitors.  Expert Opin Investig Drugs. 2000; 9: 2923-2934.
  13. Walczak J, Wood H, Wilding G, Carducci M. Prostate cancer prevention strategies using anti-proliferative or differentiating agents.  Urol. 2001; 57(4A):81-85.
  14. Carducci MA.  New chemotherapeutic approaches to hormone refractory prostate cancer. Cancer Control. 2001; 8: 62-65.
  15. Levy MH, Weinstein SM, Carducci MA.  Palliative Care.  Cancer Control. 2001; 8: 66-71.
  16. Kopetz S, Nelson JB, Carducci MA.  Endothelin-1 as a therapeutic target in prostate cancer.  Inv New Drug. 2002; 20:173-182.
  17. Walczak J, Carducci MA.  Pharmacologic therapies for prostate cancer.  Expert Opin Investig Drugs. 2002; 11: 1737-1748.
  18. Rosenbaum E, Carducci MA.  Pharmacotherapy of hormone refractory prostate cancer: New developments and challenges.  Expert Opin Pharmaocther. 2003; 4: 875-887.
  19. Lassiter LK, Carducci MA.  New approaches for the prevention of bone metastases in patients with prostate cancer: A review of preclinical and clinical studies.  Am J Cancer. 2003; 2: 181-199.
  20. Spira AI, Carducci MA.  Differentiation therapy.  Current Opin Pharmacol.  2003; 3: 338-343.
  21. Carducci MA.  Clinical trials of the endothelin-A receptor antagonist atrasentan in prostate cancer.   Cancer Conference Highlights 2003; 7: 6-8.
  22. Kahn M, Carducci MA, Partin AW.  The emerging role of docetaxel in the management of androgen independent prostate cancer.  J Urol. 2003; 170: 1709-1716.
  23. Lassiter LK, Carducci MA.  Endothelin receptor antagonists in the treatment of prostate cancer.  Semin Oncol. 2003; 30(5): 677-687.
  24. Dreicer R, Carducci M.  E1899 – An Eastern Cooperative Oncology Group study comparing ketoconazole and hydrocortisone with docetaxel and estramustine in asymptomatic, androgen independent prostate cancer patients with a rising PSA.   Reviews in Urology. 2003; 5 (S3): S52-S58.
  25. Walczak JR, Carducci MA.  Rising PSA in patients with asymptomatic hormone refractory prostate cancer.  Urology. 2003; 62 (Supp 6B): 141-146.
  26. Carducci MA, Tewari A, Bartsch G, Brawer MK, Crawford ED, D’Amico AV, Petrylak DP, Wilt TJ.  Prostate cancer update: Advanced disease.  Reviews in Urology. 2003; 5(S6): S47 –53.
  27. Petrylak DP, Abrahamson P-A, Bartsch G, Carducci MA. Small EJ, Wilding G.  Hormone-refractory prostate cancer: New Horizons.  Reviews in Urology. 2003; 5(S6): S54–58.
  28. Carducci MA.  Genitourinary Cancers –Highlights from the 40th Annual Meeting of the American Society of Clinical Oncology.  Clin Advanc Hematol Oncol. 2004; 2: 521-522.
  29. Jimeno A, Carducci MA.  Atrasentan: Targeting the endothelin axis in cancer.  Expert Opin Invest Drugs. 2004; 13: 1631-1640.
  30. Khan MA, Carducci MA, Partin AW.  Docetaxel in androgen-independent prostate cancer: an update.  BJU Int. 20004; 94: 1209-1210.
  31. Alumkal JJ, Carducci MA.  The early use of chemotherapy in conjunction with radical prostatectomy.  Clin Prostate Cancer. 2004; 3: 144-149.
  32. Walczak JR, Carducci MA.  The use of docetaxel in prostate cancer: A commentary on the Eastern Cooperative Oncology Group Study E1899.   Am J Urol Review. 2004; 2 (S9): 1-5.
  33. Shabbeer S, Carducci MA.  Targeting deacetylation for therapeutic benefit.  IDrugs.  2005; 8: 144-154.
  34. Browner I, Carducci MA.  Palliative chemotherapy: Historical perspective, applications, and controversies.  Semin Oncol.  2005; 32: 145-155.
  35. Armstrong AJ, Carducci MA. Novel therapeutic approaches to advanced prostate cancer.  Clin Advances Hematol Onco. 2005; 3: 271- 282.
  36. Armstrong AJ, Carducci MA.  Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.  Curr Oncol Rep. 2005; 7: 220-227.
  37. Armstrong A, Carducci MA.  Advanced prostate cancer: The future.  Canadian J Urol. 2005; 12 (Suppl 2): 42-47.
  38. Jimeno A, Carducci M.  Atrasentan: A novel and rationally designed therapeutic alternative for the management of cancer.  Expert Review of Anticancer Therapy. 2005; 5: 419-427.
  39. Armstrong AJ, Carducci MA. New drugs in prostate cancer.  Curr Opin Urol. 2006; 16: 138-145.
  40. Jimeno A, Carducci M.  Atrasentan: A rationally designed targeted therapy for cancer.  Drugs Today. 2006; 42: 299-312.
  41. Heath EI, Carducci MA. New targets in the management of prostate cancer.  Hematol Oncol Clin N Am.  2006; 20: 985-999.
  42. Carducci MA, Jimeno A.  Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.  Clin Cancer Res. 2006; 12: 6296s-6300s.
  43. Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG.  Novel targets in solid tumors: MEK Inhibitors. Clin Advances Hematol Onco. 2006; 4: 831-836.
  44. Kortenhorst MSQ, Carducci MA, Shabbeer S. Acetylation and histone deacetylase inhibitors in cancer.  Cellul Oncol. 2006; 28: 191-222.
  45. Walczak JR, Carducci MA.  Prostate cancer: A practical approach to current management of reccurrent disease.  Mayo Clinic Proc, 2007; 82:243-249.
  46. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI.  Department of Defense Prostate Cancer Clinical Trials Consortium: A new instrument for prostate cancer clinical research.  Clin Genitourinary Cancer, 2009; 7:51-57. 
  47. Wissing M, Rosmus N, Carducci M, Kachhap S. NDRG1 (N-myc downstream regulated 1). Atlas Genet Cytogenet Oncol Haematol. October 2009.
  48. Antonarakis E, Carducci MA, Eisenberger MA.  Novel targeted therapeutics for metastatic castration-resistant prostate cancer.  Cancer Lett 2010; 291:1-13. Epub 2009 Aug 29. 
  49. Lin J, Denmeade S, Carducci MA.  HIF-1α and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides.  Current Cancer Drug Targets. 2009; 9:881-887.
  50. Antonarakis ES, DeMarzo AM, Deweese TL, Carducci MA.  Reply to P. Mathew.  J Clin Oncol. 2010 Feb 22 [Epub ahead of print]
  51. Antonarakis ES, Carducci MA.  Future directions in castrate-resistant prostate cancer therapy.  Clin Genitourin Cancer, 2010; 8:37-46. 
  52. Bardia A, Carducci MA.  Localized prostate cancer: What the medical oncologist needs to know.  US Hematol Oncol, 2011; 7: X.
  53. Hudes GR, Carducci MA. Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson D, Motzer RJ, Pili R, Roethke S, Srinivas S.  NCCN Task Force Report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.  JNCCN, 2011: 9:S1-S29.
  54. Beltran H, Beer T, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.  New therapies for castration-resistant prostate cancer: efficacy and safety.  Eur Urol, 2011; 60: 279-290. Epub 2011 May 4.
  55. George S, Pili R, Carducci MA, Kim JJ.  Role of immunotherapy for renal cell cancer in 2011.  J Natl Compr Canc Netw. 2011; 9: 1011-1018.
  56. Connolly R, Carducci MA, Antonarakis ES.  Use of androgen deprivation therapy in prostate cancer: Indications and prevalence.  Asian J Androl. 2012; 14:177-188. Epub 2012 Jan 9. 
  57. Antonarakis ES, Carducci MA.  Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets, 2012; 16:365-376. Epub 2012 Mar 13. 
  58. Paller CJ, Carducci MA.  Philips GK.  Management of bone metastases in refractory prostate cancer- role of denosumab.  Clin Interventions in Aging.  2012; 7: 363-372.  Epub 2012 Sep 17.
  59. Schweizer MT, Carducci MA.  From bevacizumab to tasquinimod: Angiogenesis as a therapeutic target in prostate cancer.  Cancer J. 2013;19: 99-106.
  60. Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA. Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am.  2013; 27: 1205-1219.  Epub 2013 Sep 18.
  61. Suzman DL, Boikos SA, Carducci MA.  Bone-targeting agents in prostate cancer.  Cancer Metastasis Rev. 2014;33:619-628.  Epub 2014 Jan 8.
  62. Van Dodewaard-de Jong JM, Bloemendal HJ, deKlerk JMH, Carducci MA, van den Eertwegh AJM. New treatment options for patients with metastatic prostate cancer: What is the optimal sequence? Clin Genitourin Cancer. 2015; 13:271-279.   Epub 2015 Jan 21. 
  63. Markowski MC, Carducci MA.  Early use of chemotherapy in metastatic prostate cancer. Cancer Treat Rev. 2016 Oct 6 [Epub ahed of print].
  64. Paller CJ, Pantuck A, Carducci MA.  A review of pomegranate in prostate cancer.  Prostate Cancer Prostatic Dis.  2017 Apr 25. [Epub ahead of print]
  65. Isaacsson Velho P, Carducci MA.  Investigational therapies targeting the androgen signaling axis and the androgen receptor in prostate cancer- recent developments and future directions. Expert Opin Investig Drugs. 2018 Aug 17. [Epub ahead of print]

 


Memberships

1990 - 92 American College of Physicians, Associate
1992 - 98 American College of Physicians, Member
1992 American Association of the Advancement of Science, Member
1993 - 96 American Association for Cancer Research, Associate
1995 - American Society of Clinical Oncology, Member
1996 - American Association for Cancer Research, Member
1997 - American Urological Association, Affiliate Member
1997 - International Society of Differentiation, Member
1998 - American College of Physicians, Fellow
1999 - National Kidney Cancer Foundation, Member
2012- European Society of Medical Oncology, Member

 


Awards & Honors

1979

Salutatorian, Bishop Moore High School

1982 Alpha Sigma Nu - Jesuit Honor Society
1986 Alpha Omega Alpha
1988 M.D. with High Distinction, Wayne State University
1988 Distinguished Service Award, Wayne State University School of Medicine
1991 Housestaff Teaching Award Department of Medicine University of Colorado Health Sciences Center
1995 Wellcome Oncology Clinical Research Scholar American Association for Cancer Research
1995 Third Prize, 1995 American Urological Association/CaP CURE Contest
1995 Young Investigator Award, American Society of Clinical Oncology
1995 Merit Award Recipient, American Society of Clinical Oncology
1995, 1996, 1997 Catherine S. and Isaac Hecht Award for Cancer Research
1996 1996 Second Prize, 1996 American Urological Association/CaP CURE Contest
1997 1997 Osler Medicine Housestaff Teaching Award, Department of Medicine, The Johns Hopkins University School of Medicine
2002 Talma Eykman Foundation Award to Fleur van de Geijn (Dr. C arducci- Mentor) for outstanding research during research elective
2003, 2004 Appel Research Program in Prostate Cancer, Research Support
2005 Director's Teaching Award for Clinical Science, Johns Hopkins Kimmel Cancer Center
2006-

Best Doctors in America

2007

Brady Urological Institute, Faculty Teacher of the Year

2009

Inaguaral Recipient of AEGON Professorship in Prostate Cancer Research

2010- 2016

Visiting Professor, CCA/V-ICI Institute, VU University Medical Center Amsterdam, The Netherlands

2011

Recipient, Michaele C. Christian Oncology Drug Development Award and Lectureship, National Cancer Institute

2011-

Baltimore’s Top Doctors, US News and World Report-Top 1%

2012,2013

Selected Washington, DC- Baltimore-Northern Virginia Super Doctors

2013 Fellow of the American Society of Clinical Oncology, FASCO
2015

Member, Miller-Coulson Academy of Clinical Excellence

2018

Web of Sciencer Highly Cited Researchers 2018, Cross-Field Contributions, Clarivate Analytics